Twelve-Month Follow-up of the Immune Response After COVID-19 Vaccination in Patients with Genitourinary Cancers: A Prospective Cohort Analysis
Meza L, Zengin Z, Salgia S, Malhotra J, Karczewska E, Dorff T, Tripathi A, Ely J, Kelley E, Mead H, Hsu J, Dizman N, Salgia N, Chawla N, Chehrazi-Raffle A, Muddasani R, Govindarajan A, Rock A, Liu S, Salgia R, Trent J, Altin J, Pal S. Twelve-Month Follow-up of the Immune Response After COVID-19 Vaccination in Patients with Genitourinary Cancers: A Prospective Cohort Analysis. The Oncologist 2023, 28: e748-e755. PMID: 36971500, PMCID: PMC10485287, DOI: 10.1093/oncolo/oyad067.Peer-Reviewed Original ResearchConceptsCOVID-19 vaccinationGenitourinary cancersRenal cell carcinomaBooster doseCell carcinomaImmune responseBlood samplesSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2T-cell receptor sequencingRespiratory syndrome coronavirus 2Baseline blood samplesMajority of patientsMinority of patientsProspective cohort analysisSyndrome coronavirus 2Twelve-month followAntibody titer analysisCOVID-19 vaccineSeroconversion ratesMedian ageUrothelial cancerCoronavirus 2Prostate cancerCohort analysisSpectrum and implications of activating BRAF alterations in advanced prostate cancer (aPC).
Chehrazi-Raffle A, Tukachinsky H, Schrock A, Hwang J, Zengin Z, Meza L, Chawla N, Ebrahimi H, Govindarajan A, Castro D, Rock A, Tripathi A, Dorff T, Pal S, Oxnard G, Agarwal N, Antonarakis E. Spectrum and implications of activating BRAF alterations in advanced prostate cancer (aPC). Journal Of Clinical Oncology 2023, 41: 220-220. DOI: 10.1200/jco.2023.41.6_suppl.220.Peer-Reviewed Original ResearchAdvanced prostate cancerComprehensive genomic profilingGenomic alterationsBRAF alterationsTissue biopsiesCancer typesFurther clinical investigationTMPRSS2-ERG fusionFoundationOne CDxMedian ageCommon genomic alterationsAPC patientsProstate cancerMolecular subtypesClinical investigationHigh incidenceActionable targetsBRAF rearrangementsCancer-related genesHotspot missense mutationsGenomic profilingBRAFCDK12 mutationsGenetic activationBiopsyEvaluation of eligibility criteria in advanced prostate cancer clinical trials based on ASCO-FCR recommendations.
Feng M, Prajapati S, Castro D, Lee K, Chan E, Sehgal I, Patel J, O'Dell A, Zengin Z, Li X, Chehrazi-Raffle A, Dizman N, Tripathi A, Rock A, Liu S, Mercier B, Meza L, Philip E, Dorff T, Pal S. Evaluation of eligibility criteria in advanced prostate cancer clinical trials based on ASCO-FCR recommendations. Journal Of Clinical Oncology 2023, 41: 34-34. DOI: 10.1200/jco.2023.41.6_suppl.34.Peer-Reviewed Original ResearchType of treatmentExclusion criteriaBrain metastasesEligibility criteriaExact testHBV/HCVMetastatic prostate cancerFisher's exact testChi-square testClinical eligibilityConcurrent malignancyHCV positivityHormone therapyHIV positivityCombination therapyRadioligand therapyClinical trialsProstate cancerProstate cancer studyRadiation therapyClinical OncologyTherapyCancer typesMeSH termsPhase I